



Press Release

| | | | |
|-------------|------------|------------------|-------------------|
| BSE: 500257 | NSE: LUPIN | REUTERS: LUPN.BO | BLOOMBERG: LPC IN |
|-------------|------------|------------------|-------------------|

Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U.S.

Mumbai, June 23, 2008

Lupin Ltd. (Lupin) announced today that the Company has entered into a promotion agreement for Suprax® 400 mg Tablets with ASCEND Therapeutics, Inc.

Under the terms of the alliance, ASCEND Therapeutics will initiate promotion of the product in the U.S. in the month of June 2008. ASCEND has a 50-person Women's Health sales force which will detail the product primarily to Obstetricians and Gynecologists (OB/GYNs). Lupin will continue to promote the product to Pediatricians and Family Practitioners.

The antibiotic market for treatment of Urinary Tract Infections (UTIs) is USD 450 million, and the OB/GYN area is among the top three physician specialties prescribing antibiotics for treatment of UTIs.

Dr. Kamal Sharma, Managing Director, Lupin, said "We are pleased to enter into this strategic alliance with ASCEND. We believe ASCEND's existing equity with the OB/GYN specialty will help Lupin to fully explore and leverage an additional opportunity for promoting Suprax® 400 mg Tablets. This alliance reflects our commitment to extend Suprax® franchise and enhance the value of brand business in the U.S."

There are over 8 million patients who suffer from UTIs each year, with the vast majority of women. Suprax® 400 mg Tablets is an established antibiotic with a favorable safety profile and proven track record in effectively treating UTIs and other bacterial infections.

About Lupin

Headquartered in Mumbai, India, **Lupin Limited** is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into New Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US\$ 694 million) and Rs.4,083 million (US\$ 102 million) respectively.

Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies.

For more information, visit <http://www.lupinpharmaceuticals.com>.

About ASCEND Therapeutics

ASCEND Therapeutics is a biopharmaceutical company focused on the use of transdermal drug delivery technology to overcome therapeutic barriers and raise the standard of care for certain chronic conditions. For more information about ASCEND, you may visit the company's web site at www.ascendtherapeutics.com.

Suprax® is a registered trademark of Lupin Pharmaceuticals, Inc.

For further information please contact:

Lupin Limited:
Seema Ahuja
Head, Corporate Communications
Mobile: +919920042046
022 66402323 Fax: 022 66402534, Email: seemaahuja@lupinpharma.com

OR

Source Strategic Communications Pvt. Ltd.
Archana Pradhan, Mobile: +919820330505, Email: archanapradhan@sourcepr.com